Preferred test for fresh specimens at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving loss/gain of DNA or loss of heterozygosity (LOH). Monitor disease progression and response to therapy.
Genomic Microarray (Oligo-SNP Array)
Green (sodium heparin). Bone marrow or peripheral blood required.
Transport 3 mL bone marrow. (Min: 1 mL) or 5 mL peripheral blood (Min: 2 mL)
Frozen specimens. Clotted specimens.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Refer to report
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test must be ordered using a Cytogenetic test request form 43099 or through your ARUP interface.
|Component Test Code*||Component Chart Name||LOINC|
|2006326||Cytogenomic Microarray SNP - Oncology|
|2006327||EER CMA ONC||11526-1|
- genomic microarray, oligo-SNP array